Immunology Program

The Michael Glickman Lab

Research

Michael Glickman
Michael S. Glickman, MD

We are broadly interested in the biology of mycobacteria, which include the major human pathogen M. tuberculosis, the nonpathogenic model organism M. smegmatis, and the cancer biotherapeutic agent BCG.

View Lab Overview

Research Projects

Michael Glickman Lab

Publications Highlights

Roles for mycobacterial DinB2 in frameshift and substitution mutagenesis, P Dupuy, S Ghosh, A Fay, O Adefisayo, R Gupta, S Shuman, …Elife 12, e83094

View All Publications

People

Michael Glickman

Michael S. Glickman, MD

  • Physician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including the use of mycobacteria as bacterial cancer therapies.
  • MD, Columbia University College of Physicians and Surgeons
[email protected]
Email Address
646-888-2368
Office Phone
View physician profile
Physician profile

Members

Michael Glickman, MD
Michael Glickman

Member

John Buglino, PhD
John Buglino

Senior Research Scientist

Allison Fay, PhD
Allison Fay

Senior Research Scientist

Gil Redelman-Sidi, MD
Gil Redelman-Sidi

Assistant Attending Physician

Jamie Bean
Jamie Bean

Assistant Lab Member, EIO Cell Bank director

Anna Benjamin

Lab Manager

Shireen Khayat

Graduate Student

Adam Krebs
Adam Krebs

Graduate Student

Yaprak Ozakman
Yaprak Ozakman

Research Scholar

Gaurav Sankhe
Gaurav Sankhe

Research Associate

Pablo Santos Molina
Pablo Santos Molina

MSK Bridge Program Scholar

Veronica Shields

Administrative Assistant

Lab Alumni
Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Michael S. Glickman discloses the following relationships and financial interests:

  • Fimbrion Therapeutics, Inc.
    Professional Services and Activities (Uncompensated)
  • Vedanta
    Equity; Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures